BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

European Medicines Evaluation Agency Wants Two More Drugs Moved From Ben Venue Laboratories Due to Ongoing Manufacturing Practice Concerns


3/20/2012 8:20:22 AM

The European Medicines Agency (EMA) has recommended the transfer of Caelyx and Ceplene manufacturing processes from the Ben Venue Laboratories in Ohio, US, to alternative facilities, due to shortcomings in quality assurance at the site. The anticancer medicines Caelyx from Janssen-Cilag and Ceplene made by EpiCept are considered to be essential for patients and no alternative suppliers or alternative formulations are presently available, the pharma letter reported. The Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that, while the transfers are ongoing, the marketing authorizations of the two drugs be maintained.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->